Therapix Biosciences (TRPXY) Stock Price, News & Analysis

Company Overview

Therapix Biosciences Ltd. (OTCMKTS: TRPXY) is a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of cannabinoid-based prescription therapeutics. The company leverages a deep understanding of the endocannabinoid system to create novel small-molecule and topical drug candidates targeting a range of neurological, inflammatory and sexual health disorders. Its research efforts center on unlocking the therapeutic potential of synthetic and plant-derived cannabinoids to address significant unmet medical needs.

Therapix’s proprietary pipeline includes multiple clinical-stage programs designed to treat conditions such as insomnia, chronic pain, inflammatory skin diseases and female sexual dysfunction. Among its key assets are topical formulations for localized inflammatory relief and orally administered compounds engineered to modulate cannabinoid receptors with precision. The company also pursues a second-generation program aimed at severe epileptic syndromes, leveraging novel formulation technologies to enhance bioavailability and patient tolerability.

In addition to its drug development activities, Therapix maintains a wholly owned subsidiary that holds a license to cultivate and distribute medical cannabis in Israel, supporting both clinical research and patient access initiatives. Through strategic partnerships and investigator-initiated studies in North America and Europe, the company is working to broaden its regulatory footprint and prepare for potential commercial launches across multiple markets. Its global network enables seamless coordination of clinical trials and streamlined supply chain management.

Founded in 2012 as Kalyra Pharmaceuticals, the company adopted the Therapix Biosciences name in 2020 to reflect its expanded focus on cannabinoid therapeutics. Its leadership team combines seasoned professionals from the pharmaceutical and biotech industries, including experts in drug development, regulatory affairs and commercial strategy. Guided by a board of directors with extensive experience in life sciences, Therapix is committed to advancing safe and effective cannabinoid-based medicines from laboratory to clinic.

Key Stats

• Today's Range: $6.00 to $6.15
• 50-Day Range: $6.03 to $6.03
• 52-Week Range: $2.75 to $22.40
• Volume: 53,500 shs
• Average Volume: 12,316 shs
• Market Capitalization: $6.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRPXY Stock Analysis - Frequently Asked Questions

How have TRPXY shares performed this year?

Therapix Biosciences' stock was trading at $6.03 at the start of the year. Since then, TRPXY stock has increased by 0.0% and is now trading at $6.03.

How do I buy shares of Therapix Biosciences?

Shares of TRPXY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRPXY
• CIK: N/A
• Web: therapixbio.com
• Phone: 972 3 616 7055
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,037,000
• Free Float: N/A
• Market Cap: $6.25 million
• Optionable: Not Optionable
• Beta: N/A